FutureChemLtd Past Earnings Performance
Past criteria checks 0/6
FutureChemLtd has been growing earnings at an average annual rate of 1%, while the Life Sciences industry saw earnings growing at 21.2% annually. Revenues have been growing at an average rate of 15.8% per year.
Key information
1.0%
Earnings growth rate
22.7%
EPS growth rate
| Life Sciences Industry Growth | 53.7% |
| Revenue growth rate | 15.8% |
| Return on equity | -10.5% |
| Net Margin | -48.0% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
FutureChem Co.,Ltd (KOSDAQ:220100) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected
Apr 29
Revenues Not Telling The Story For FutureChem Co.,Ltd (KOSDAQ:220100)
Feb 26Is FutureChemLtd (KOSDAQ:220100) Using Debt In A Risky Way?
Feb 05
What Percentage Of FutureChem Co.,Ltd (KOSDAQ:220100) Shares Do Insiders Own?
Dec 14Revenue & Expenses BreakdownBeta
How FutureChemLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 13,968 | -6,709 | 6,808 | 2,358 |
| 30 Sep 23 | 13,589 | -10,207 | 6,893 | 5,277 |
| 30 Jun 23 | 12,992 | -12,312 | 6,480 | 7,299 |
| 31 Mar 23 | 13,020 | -12,114 | 6,333 | 6,998 |
| 31 Dec 22 | 12,574 | -13,959 | 6,149 | 7,645 |
| 30 Sep 22 | 11,705 | -10,391 | 5,702 | 4,910 |
| 30 Jun 22 | 11,208 | -8,561 | 5,621 | 3,556 |
| 31 Mar 22 | 11,090 | -9,077 | 5,491 | 4,901 |
| 31 Dec 21 | 11,818 | -3,420 | 5,385 | 4,174 |
| 30 Sep 21 | 12,913 | -16,260 | 5,131 | 3,807 |
| 30 Jun 21 | 13,058 | -16,613 | 4,970 | 3,498 |
| 31 Mar 21 | 12,740 | -16,645 | 4,977 | 1,881 |
| 31 Dec 20 | 11,013 | -23,101 | 4,877 | 1,937 |
| 30 Sep 20 | 9,879 | -9,147 | 4,728 | 1,633 |
| 30 Jun 20 | 9,339 | -9,760 | 4,637 | 1,429 |
| 31 Mar 20 | 8,320 | -7,498 | 4,390 | 1,197 |
| 31 Dec 19 | 8,167 | -5,368 | 4,356 | 877 |
| 30 Sep 19 | 6,202 | -10,925 | 4,645 | 774 |
| 30 Jun 19 | 5,675 | -10,125 | 4,593 | 726 |
| 31 Mar 19 | 5,518 | -11,963 | 4,738 | 670 |
| 31 Dec 18 | 5,635 | -11,969 | 4,598 | 649 |
| 30 Sep 18 | 5,616 | -7,520 | 3,886 | 807 |
| 30 Jun 18 | 4,871 | -6,433 | 3,865 | 645 |
| 31 Mar 18 | 4,151 | -5,042 | 3,401 | 614 |
| 31 Dec 17 | 2,998 | -4,491 | 3,129 | 629 |
| 30 Sep 17 | 2,049 | -3,887 | 2,819 | 660 |
| 31 Dec 16 | 1,625 | -27,286 | 1,966 | 385 |
| 31 Dec 15 | 1,447 | -24,529 | 1,695 | 175 |
| 31 Dec 14 | 703 | -3,905 | 715 | 152 |
Quality Earnings: A220100 is currently unprofitable.
Growing Profit Margin: A220100 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A220100 is unprofitable, but has reduced losses over the past 5 years at a rate of 1% per year.
Accelerating Growth: Unable to compare A220100's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A220100 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (7.5%).
Return on Equity
High ROE: A220100 has a negative Return on Equity (-10.5%), as it is currently unprofitable.